Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.
An improved number of anti-fungal drugs are currently available for the treatment of invasive aspergillosis (IA). While serial galactomannan index (GMI) measurement can be used to monitor response to treatment, the extent to which different anti-fungal regimens can affect galactomannan levels is unk...
Main Authors: | Louis Yi Ann Chai, Bart Jan Kullberg, Arul Earnest, Elizabeth M Johnson, Steven Teerenstra, Alieke G Vonk, Haran T Schlamm, Raoul Herbrecht, Mihai G Netea, Peter F Troke |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3938651?pdf=render |
Similar Items
-
Resolution of orbitocerebral aspergillosis during combination treatment with voriconazole and amphotericin plus adjunctive cytokine therapy.
by: Bethell, D, et al.
Published: (2004) -
Invasive aspergillosis: Is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
by: G Schnetzler, et al.
Published: (2006-10-01) -
Fluconazole, caspofungin, voriconazole in combination with amphotericin B
by: Kalkanci Ayse, et al.
Published: (2010-04-01) -
Invasive Pulmonary Aspergillosis
by: Marie-Pierre Ledoux, et al.
Published: (2023-01-01) -
Galactomannan antigen as one of the markers for the diagnosis of invasive aspergillosis
by: O.O. Yastremska, et al.
Published: (2019-12-01)